Elevating Our Communities With Every Interaction

Velocity is the world's leading integrated site organization.

Sponsors and CROs trust Velocity to deliver high-quality clinical trial data and patient care with unprecedented efficiency.

Simplify everything from site selection to study close-out

Velocity unifies operational processes to provide world-class sites, reliable enrollment, and predictably high performance for your trials.

Research sites across the U.S. and Europe
+
Investigators with diverse experience
+
Clinical trials conducted since 1986
treatment
mother-and-child-2
Hallandale
caring african medical nurse comforting senior patient in office
Velocity-team-office

The right sites.
The right investigators.
The right partner for you.

Strategically located to give you access to diverse specialty populations, Velocity's sites are supported by next-gen technologies and patient engagement capabilities. Welcome to recruitment and retention reimagined.

Scale for a purpose: Supporting research programs worldwide

From the leading pharma companies, to the most pioneering biotech startups, Velocity supports those who are exploring new frontiers in human health.

Whether you’re ready to conduct a single-site study or a complex, high-volume clinical trial, contact Velocity.

News

ACRP Article: Providing the Blueprint for Gen AI Adoption in Clinical Trials

October 10, 2024

In his latest article for the Association of Clinical Research Professionals (ACRP), Paul Evans outlines how integrated site organizations can pave the way for AI adoption and generate tangible value … Read more

Closing Trust Gaps: The Economic Case for Enhancing Health Equity in Clinical Trials

October 9, 2024

The pandemic left many notable developments in its wake, not least the increased focus on improving diversity in clinical trials. This issue was thrust into the spotlight during Operation Warp … Read more

Nick Spittal Comments on Velocity’s Membership With Advarra’s Gene Therapy Ready Site Network

October 3, 2024

As Nick Spittal states in this Advarra press release, membership in the Gene Therapy Ready (GTR) site network “allows Velocity to start studies over a month faster and provides a … Read more

VISION Reaches $2.5 Million in Patient Stipends Paid Globally

October 1, 2024

Another major milestone for Velocity — more than $2.5 million in patient study stipends have been paid globally through our VISION Engage app! With VISION Engage, patients can seamlessly manage … Read more

Quality. Continuity. Velocity.